Non-Alcoholic Steatohepatitis (NASH) is a form of sterile inflammation that is driven by obesity, metabolic syndrome and type 2 diabetes. It can progress to fibrosis, cirrhosis, and liver cancer. There are no approved therapies. By 2020, NASH will be the leading cause for liver transplants.

About OCR 7314:

• A novel oligonucleotide antagonist of TLR7/9.
• Excellent Phase 1 safety and tolerability data; Phase 2 safety data.
• Strong in vitro and in vivo efficacy in the HFD mouse models of NASH.
• Unique mechanism of action: targets inflammation and oxidative stress pathways that lead to liver fibrosis, while majority of current NASH drug candidates (18 out of 27 active NASH programs) target metabolic component of the disease.
• Biopharma-developed drug, in-licensed by Yale for clinical development for new indications, including NASH and liver fibrosis.

IP status: 7 issued patents, extending to 2030; Clinical data package and Right of Reference to active IND.

Lead Inventor: Wajahat Mehal, M.D., D. Phil.